Back to Directory
Erenumab
Performance & EnduranceAnti-CGRP receptor monoclonal antibody for migraine prevention, first in class approved.
Key Benefits
- ✓First CGRP-targeted therapy approved
- ✓Prevents migraines
- ✓Blocks CGRP receptor
- ✓Monthly dosing
- ✓Well tolerated
Dosing Information
Dosage Range
70-140 mg
Frequency
Monthly
Typical Duration
Ongoing
Detailed Protocol
Administered via subcutaneous injection monthly using autoinjector pen. Can be self-administered. Available in 70mg and 140mg doses. Prescription required.
About Erenumab
Erenumab (Aimovig) is a fully human monoclonal antibody that blocks the CGRP receptor (rather than ligand). First CGRP-targeting therapy FDA-approved for migraine prevention. Monthly subcutaneous injection.
Research Notes
FDA-approved in 2018, first CGRP therapy for migraine. Blocks receptor rather than ligand (different from other CGRP antibodies). Revolutionized migraine prevention. Monthly self-injection.
Potential Side Effects
- •Injection site reactions
- •Constipation
- •Muscle spasms
- •Hypertension (rare)
- •Generally well tolerated
Always consult with a healthcare professional before starting any peptide therapy.